BiotechTube

BIW-8962

Phase 1/2Terminated
0 watching 0 views this week⚡ Active
41
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Phase 1 Portion : Non Small Cell Lung Cancer(NSCLC), Small Cell Lung Cancer(SCLC), Mesothelioma

Conditions

Phase 1 Portion : Non Small Cell Lung Cancer(NSCLC), Small Cell Lung Cancer(SCLC), Mesothelioma, Phase 2 Portion : Small Cell Lung Cancer(SCLC)

Trial Timeline

Jul 1, 2013 → Jun 1, 2016

NCT ID
NCT01898156

About BIW-8962

BIW-8962 is a phase 1/2 stage product being developed by Kyowa Kirin for Phase 1 Portion : Non Small Cell Lung Cancer(NSCLC), Small Cell Lung Cancer(SCLC), Mesothelioma. The current trial status is terminated. This product is registered under clinical trial identifier NCT01898156. Target conditions include Phase 1 Portion : Non Small Cell Lung Cancer(NSCLC), Small Cell Lung Cancer(SCLC), Mesothelioma, Phase 2 Portion : Small Cell Lung Cancer(SCLC).

Hype Score Breakdown

Clinical
13
Activity
8
Company
10
Novelty
4
Community
3

Clinical Trials (2)

NCT IDPhaseStatus
NCT01898156Phase 1/2Terminated
NCT00775502Phase 1Terminated

Competing Products

20 competing products in Phase 1 Portion : Non Small Cell Lung Cancer(NSCLC), Small Cell Lung Cancer(SCLC), Mesothelioma

See all competitors
ProductCompanyStageHype Score
TERN-701Terns PharmaceuticalsPhase 1/2
38
Tamsulosin HCl + Solifenacin Succinate + EC905Astellas PharmaPhase 1
33
solifenacin succinate + mirabegron + mirabegron/solifenacin succinateAstellas PharmaPhase 1
33
Graceptor®Astellas PharmaPre-clinical
23
Lemborexant + PlaceboEisaiApproved
85
AcalabrutinibAstraZenecaPhase 1/2
41
Sacituzumab tirumotecanMerckPhase 2
52
progesterone + ProgesteroneMerckApproved
85
AsciminibNovartisPre-clinical
23
NilotinibNovartisPhase 3
77
Imatinib mesylateNovartisPhase 3
77
Imatinib Mesylate 600 MG Oral Tablet + Imatinib Mesylate 400 MG Oral Tablet + Imatinib MesylateNovartisPhase 3
77
ribociclib + TrametinibNovartisPhase 1
33
NilotinibNovartisApproved
85
ImatinibNovartisPhase 3
77
NilotinibNovartisApproved
85
GleevecNovartisPhase 2
52
Nilotinib + RuxolitinibNovartisPhase 1/2
41
ABL001NovartisPhase 3
77
asciminibNovartisPhase 2
52

Other Products from Kyowa Kirin

KRN23Approved
85
Istradefylline PillApproved
85
MogamulizumabApproved
85
KRN23Approved
85
KHK4827-Active + KHK4827-PlaceboApproved
85